Chemo Added to Surgery Ups OS in Gastric Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Patients who receive chemotherapy after surgery for gastric cancer have a higher rate of survival compared to those patients who have surgery alone.

Patients who receive chemotherapy after surgery for gastric cancer have a higher rate of survival compared to those patients who have surgery alone.

Xavier Paoletti, PhD, of the Institut National du Cancer in Boulogne, France, and colleagues with the Global Advanced/Adjuvant Stomach Tumor Research International Collaboration (GASTRIC) Group, performed a meta-analysis to assess the benefit of adjuvant chemotherapy. They identified 31 eligible trials (6,390 patients) and, as of 2010, individual patient data were available from 17 trials (3,838 patients representing 60% percent of the targeted data) with a median follow up exceeding seven years.

They found that there were 1,000 deaths among 1,924 patients assigned to chemotherapy groups and 1,067 deaths among 1,857 patients assigned to surgery-only groups.

The estimated median overall survival (OS) was 4.9 years in the surgery-only group vs 7.8 years in the group receiving adjuvant chemotherapy.

An absolute improvement of about 6% in OS was observed after five years and maintained at 10 years. Five-year OS increased from 49.6% to 55.3% with chemotherapy (JAMA 303:1729-1737, 2010).

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content